Download PDF
Nervenheilkunde 2015; 34(03): 161-166
DOI: 10.1055/s-0038-1627572
Parkinson
Schattauer GmbH

Gibt es eine Pharmakotherapie von “herausforderndes Verhalten”?

Patienten mit Demenz und Parkinson-SyndromIs there a pharmacotherapy of “challenging behavior”?Patients with dementia and parkinsonism
J. Hansmann
1   Abt. Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München Schwabing
,
A. Ceballos-Baumann
1   Abt. Neurologie und klinische Neurophysiologie mit Parkinson-Fachklinik, Schön Klinik München Schwabing
› Author Affiliations
Further Information

Publication History

eingegangen am: 22 January 2015

angenommen am: 22 January 2015

Publication Date:
22 January 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nicht kognitive Demenz-Symptome wie Agitation und Aggression, eventuell begleitet von produktiven Symptomen wie Halluzinationen und Wahnvorstellungen sind als “herausforderndes Verhalten” konzeptualisiert worden, um die Verantwortungszuweisung an den Erkrankten zu verhindern. Auch Depression und Apathie werden darunter subsumiert, wenn dies zu Konflikten mit den versorgenden Personen führt. Die Gabe von Neuroleptika bei älteren Menschen birgt die Gefahr von einer erhöhten Mortalität sowie von einem erhöhten Risiko zerebrovaskulärer Ereignisse. Nichtsdestotrotz gibt es Situationen im klinischen Alltag bei der Behandlung dementer Patienten, die eine neuroleptische Therapie erfordern. Insgesamt gesehen sind die psychopharmakologischen Behandlungsmöglichkeiten von herausforderndem Verhalten ernüchternd. Bei Patienten, die eine Demenz und ein Parkinson-Syndrom haben, ist die Pharmakotherapie zusätzlich erschwert. Einzige Neuroleptika, die bei Parkinson-Syndromen in Frage kommen, sind Clozapin (on-label für Psychose, nicht “herausforderndes Verhalten”) und Quetiapin (off-Label). Cholinesterasehemmer sind auch bei Patienten mit Parkinson-Syndrom zu erwän. Studiendaten legen einen Einsatz von Citalopram bei Agitation nahe.

Summary

“Challenging behaviour” is the term used for non-cognitive symptoms of dementia such as agitation and aggression. It can include productive symptoms such as hallucinations and delusions. For more than ten years it is known that antipsychotic drugs will increase mortality in elderly people and the risk of cerebrovascular events. Nevertheless, there are situations with challenging behavior which require drug therapy. However, psychopharmacological treatment options are scarce. In patients with parkinsonism in addition to dementia pharmacotherapy is even more difficult. In this instance, clozapine (on-label for psychosis, but not for non-cognitive dementia symptoms) and quetiapine (off-label) could be used as neuroleptic. New data suggest citalopram for the treatment of agitation in dementia.

Schlüsselwörter

Herausforderndes Verhalten - Demenz - Neuroleptika

Keywords

Challenging behaviour - dementia - antipsychotic drugs
 

  • Literatur

  • 1 Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 08 (07) 613-8.
    CrossrefPubMedGoogle Scholar
  • 2 Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006 (1): CD003476.
    PubMedGoogle Scholar
  • 3 Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21 (11) 1899-907.
    CrossrefPubMedGoogle Scholar
  • 4 Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladstrom A, Jones R. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, doubleblind, placebo-controlled trial. Lancet Neurol 2010; 09 (10) 969-77.
    CrossrefPubMedGoogle Scholar
  • 5 FDA. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.htm 2005
    PubMedGoogle Scholar
  • 6 Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18 (05) 510-4.
    CrossrefPubMedGoogle Scholar
  • 7 Forbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. Cochrane Database Syst Rev. 2014 02. CD003946.
    Google Scholar
  • 8 Forrester LT, Maayan N, Orrell M, Spector AE, Buchan LD, Soares-Weiser K. Aromatherapy for dementia. Cochrane Database Syst Rev. 2014 02. CD003150.
    Google Scholar
  • 9 Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55 (06) 789-94.
    CrossrefPubMedGoogle Scholar
  • 10 Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson’s disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998; 65 (05) 774-7.
    CrossrefPubMedGoogle Scholar
  • 11 Group TFCPS. Clozapine in drug-induced psychosis in Parkinson’s disease. Lancet 1999; 353 (9169): 2041-2.
    CrossrefPubMedGoogle Scholar
  • 12 Haupt M, Karger A, Baumgartner D, Kuminoti D, Janner M, Schneider F. [Improvement of agitation and anxiety in dementia patients after psychoeducative training of their caregivers]. Fortschr Neurol Psychiatr 2000; 68 (05) 216-23.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43 (01) 69-72.
    CrossrefPubMedGoogle Scholar
  • 14 Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010; 107 (31–32): 543-51.
    PubMedGoogle Scholar
  • 15 Jessen F, Spottke A, Maier G. et al. Interdisziplinäre Leitlinie der DGPPN und DGN S3-Leitlinie Demenzen. Berlin: 2009
    Google Scholar
  • 16 Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68 (17) 1356-63.
    CrossrefPubMedGoogle Scholar
  • 17 Lemke MR. Effect of carbamazepine on agitation in Alzheimer’s inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56 (08) 354-7.
    PubMedGoogle Scholar
  • 18 Lonergan ET, Cameron M, Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev. 2004 (2): CD003945.
    PubMedGoogle Scholar
  • 19 Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev. 2006 (1): CD004747.
    PubMedGoogle Scholar
  • 20 Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Bottomley G, Libow L. Opioid treatment for agitation in patients with advanced dementia. Int J Geriatr Psychiatry 2003; 18 (08) 700-5.
    CrossrefPubMedGoogle Scholar
  • 21 Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55 (06) 795-9.
    CrossrefPubMedGoogle Scholar
  • 22 McGaffigan S, Bliwise DL. The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging 1997; 10 (01) 10-7.
    CrossrefPubMedGoogle Scholar
  • 23 McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356 (9247): 2031-6.
    CrossrefPubMedGoogle Scholar
  • 24 Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley Jr. CM, Feldman PD, Mintzer JE, Beckett LM, Breier A. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26 (04) 494-504.
    CrossrefPubMedGoogle Scholar
  • 25 Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatmentresistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 09 (04) 400-5.
    CrossrefGoogle Scholar
  • 26 Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergicinduced hallucinations. Mov Disord 2002; 17 (05) 1031-5.
    CrossrefPubMedGoogle Scholar
  • 27 Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 2005; 20 (08) 958-63.
    CrossrefPubMedGoogle Scholar
  • 28 Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA. A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15 (11) 942-52.
    CrossrefPubMedGoogle Scholar
  • 29 Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama 2014; 311 (07) 682-91.
    CrossrefPubMedGoogle Scholar
  • 30 Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22 (03) 313-8.
    CrossrefPubMedGoogle Scholar
  • 31 Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17 (04) 676-81.
    CrossrefPubMedGoogle Scholar
  • 32 Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355 (15) 1525-38.
    CrossrefPubMedGoogle Scholar
  • 33 Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 (2): CD008191.
    PubMedGoogle Scholar
  • 34 Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, Irvine C. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155 (01) 54-61.
    CrossrefPubMedGoogle Scholar
  • 35 Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003 (3): CD003672.
    PubMedGoogle Scholar